Fascin Inhibitors Decrease Cell Migration and Adhesion While Increase Overall Survival of Mice Bearing Bladder Cancers

Cancers

Xin-Yun Huang¹  Yufeng Wang¹  Zhankui Zhao¹  J.Jillian Zhang² 

[1] Department of Physiology and Biophysics, Weill Cornell Medical College of Cornell University, New York, NY 10065, USA;Novita Pharmaceuticals, Inc., New York, NY 10065, USA;

关键词: fascin;    tumor metastasis;    cytoskeleton;    bladder cancer;    cisplatin;    anti-PD-1;   

DOI  :  10.3390/cancers13112698

来源: DOAJ

【 摘 要 】

Bladder cancer is one of the most common cancers in the world. Early stage bladder tumors can be surgically removed, but these patients usually have relapses. When bladder cancer becomes metastatic, survival is very low. There is an urgent need for new treatments for metastatic bladder cancers. Here, we report that a new fascin inhibitor decreases the migration and adhesion of bladder cancer cells. Furthermore, this inhibitor decreases the primary tumor growth and increases the overall survival of mice bearing bladder cancers, alone, as well as in combination with the chemotherapy medication, cisplatin, or the immune checkpoint inhibitor, anti-PD-1 antibody. These data suggest that fascin inhibitors can be explored as a new treatment for bladder cancers.

【 授权许可】

Unknown